Geron Corporation (BIT:1GERN)

Italy flag Italy · Delayed Price · Currency is EUR
1.056
+0.084 (8.70%)
At close: Oct 31, 2025
8.70%
Market Cap696.98M
Revenue (ttm)140.03M
Net Income (ttm)-74.94M
Shares Outn/a
EPS (ttm)-0.11
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume6,000
Average Volume940
Open1.108
Previous Close0.971
Day's Range1.056 - 1.108
52-Week Range0.950 - 1.390
Betan/a
RSI48.49
Earnings DateNov 5, 2025

About Geron

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1990
Employees 229
Stock Exchange Borsa Italiana
Ticker Symbol 1GERN
Full Company Profile

Financial Performance

In 2024, Geron's revenue was $76.99 million, an increase of 32386.92% compared to the previous year's $237,000. Losses were -$174.57 million, -5.19% less than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.